Healthcare Industry News: IRX Therapeutics
News Release - January 25, 2008
Carol R. Epstein, M.D. Joins IRX Therapeutics As Chief Medical OfficerNEW YORK--(HSMN NewsFeed)--IRX Therapeutics, a privately-held company dedicated to the development and commercialization of novel drugs for the treatment of cancer and viral diseases, today announced that Carol R. Epstein, M.D. has joined the Company as Chief Medical Officer. She is responsible for all activities related to clinical development and medical affairs.
“We are pleased to welcome Dr. Epstein to our team," said John W. Hadden II, President & Chief Executive Officer. “Dr. Epstein has an outstanding track record and her clinical development and regulatory experience has already proven to be extremely valuable as we move toward a pivotal Phase 3 global clinical trial of our lead product, IRX-2.”
Dr. Epstein will remain Executive Vice President of MediVector where she is responsible for strategic clinical planning, creating a novel electronic data capture and reporting system, and project management for biotechnology and pharmaceutical companies. Since 1994, she has also been President of BioLogics Services, a consulting organization targeting the drug development needs of the emerging pharmaceutical community.
From 1990-1994, she served as Vice President, Chief Medical Officer of Immunogen, Inc. where she was responsible for all clinical development activities and medical affairs. Previous experience includes positions at Immunex Corporation and at Ayerst Laboratories and as a clinical physician. She holds a B.S. degree from M.I.T. and a M.D. from Yale University School of Medicine.
“I am excited to join IRX Therapeutics as we prepare for our End of Phase 2 FDA meeting scheduled for next month. The preliminary safety and efficacy data of this recently completed trial appear to confirm the encouraging data from a previously completed Phase 2a clinical trial,” said Dr. Epstein.
IRX Therapeutics discovers and develops therapeutic treatments that act on multiple cellular targets to restore the immune system’s ability to treat cancer and viral diseases. IRX-2 seeks to correct both dendritic cell and T-cell defects to stimulate an immune response to destroy tumor cells. IRX-2 received Fast Track designation by the Food and Drug Administration in November of 2003. An open label Phase 2a clinical trial in late-stage head and neck cancer patients was completed which demonstrated statistically significant improvement in the treatment group and a clinical response rate of 38%. After forty-eight months, the overall survival of IRX-2 treated patients was 61% versus 32% for the concurrent institutional control group.
About IRX Therapeutics
IRX Therapeutics is a privately held immunotherapy company focusing on the development and commercialization of treatments for advanced cancer and viral diseases. Founded in 1994 by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology,
IRX Therapeutics is developing an innovative approach that stimulates a coordinated cellular immune response to treat human diseases. The Company's product pipeline includes IRX-2, a therapeutic cancer therapy that seeks to stimulate a cellular immune response in the host to destroy tumor cells. Other products in development similarly seek to stimulate a cellular immune response for the treatment of other cancers and viral diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages, and T-cells.
For more information on IRX Therapeutics, please visit the Company’s website at http://www.irxtherapeutics.com.
Source: IRX Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.